NordiStack 4 300mg/ml 10ml Vial by Nordi Pharma

Usage

1. Confirm the vial label specifies all four actives — Nandrolone Decanoate, Boldenone Undecylenate, Testosterone Enanthate, Methenolone Enanthate — and the 300mg/ml total concentration before drawing.
2. Warm the vial to room temperature if stored cool; oil viscosity at lower temperatures can affect volume accuracy when drawing from a multi-dose vial.
3. Wipe the rubber stopper with a 70% isopropyl alcohol swab and allow it to dry fully before inserting the drawing needle.
4. Draw your calculated volume using an 18–21G needle, then switch to a finer injection needle (23–25G) for intramuscular administration to minimise tissue disruption.
5. Rotate injection sites systematically — glutes, quads, and delts are appropriate for the oil volume associated with this 300mg/ml blend — and allow each site adequate recovery time between uses.
6. Log each injection date: because four esters with different half-lives (7–14 days) are active simultaneously, tracking dose timing is essential for accurate PCT window calculation and monitoring each compound's mechanistic contribution.

Warnings

Frequently asked questions

How does each of the four compounds in NordiStack 4 bind to the androgen receptor differently?

Each compound engages AR through a distinct structural class. Nandrolone Decanoate (19-nor) binds with ~125% the anabolic potency of testosterone but also activates progesterone receptors. Boldenone Undecylenate binds AR with moderate affinity while triggering erythropoiesis via EPO pathways independently. Testosterone Enanthate is the full androgenic base. Methenolone Enanthate, a DHT derivative, binds AR without converting to oestrogen — four different binding profiles from one injection.

What does methenolone's DHT-derived chemical lineage mean for its role in the NordiStack 4 formula?

Methenolone Enanthate's DHT lineage means it cannot be aromatised by CYP19A1 enzymes and carries no progestogenic activity. Within the quad-ester matrix, this creates a pharmacological counterweight: while testosterone aromatises and nandrolone activates progesterone receptors, methenolone contributes pure AR stimulation with no additional oestrogenic or progestogenic load, and its SHBG competition effect increases the fraction of free testosterone available to tissues.

Why does boldenone's receptor affinity operate differently from the other three actives in this blend?

Boldenone Undecylenate's primary distinction is that its most significant physiological output — erythropoietic red blood cell stimulation via renal EPO upregulation — runs as a second mechanism alongside AR binding, not through it. The other three actives in NordiStack 4 produce their main anabolic effects predominantly via direct AR occupancy. Boldenone's dual-channel action, operating across a ~14-day undecylenate ester window, is why it is chosen as the erythropoietic pillar of complex mass protocols.

How should NordiStack 4 in a 10ml vial be stored after the first puncture?

After the stopper is first punctured, store the 10ml vial at room temperature (15–25°C) away from direct light, and use within 28 days. Refrigeration is not required but acceptable; if refrigerated, allow the vial to reach room temperature before drawing to reduce oil viscosity and ensure accurate volume measurement. Avoid freezing, which can alter the carrier-oil matrix.

What is the correct approach to drawing NordiStack 4 from a multi-dose vial to maintain accuracy across all four ester fractions?

Because all four esters are dissolved homogeneously in the carrier oil rather than suspended, no agitation is required before drawing. Use an 18–21G drawing needle to fill the syringe cleanly, then switch to an injection-grade needle. Wipe the stopper with an alcohol swab before each puncture. A 1–2ml syringe provides the most precise volume control for doses at or below 1ml per site. (2) angle_used

Manufacturer

NordiStack 4 is packaged in Nordi Pharma's standard 10ml borosilicate glass multi-dose vial — a format chosen for the quad-ester blend specifically because the four-compound oil solution requires a container volume that supports multiple precise draws across a full dosing cycle without compromising sterility. The vial closure system uses a bromobutyl rubber stopper rated for repeated puncture under clinical-grade conditions, sealed with an aluminium crimp collar whose colour coding is batch-specific, allowing visual batch differentiation at the point of use. Nordi Pharma's labelling architecture for NordiStack 4 prints all four active ingredients, their individual concentrations (approximately 75mg/ml each), and the total concentration (300mg/ml) directly on the primary label — a transparency standard the brand applies across its entire injectable catalogue. Each 10ml vial in the NordiStack 4 production lot is released only after HPLC quantification of all four ester fractions and LAL endotoxin clearance testing confirm the batch meets specification; that release record is linked to the vial's batch code and available to customers on request through Nordi Pharma's dedicated documentation channel.